No Data
Guizhou Yibai Pharmaceutical (600594.SH): Currently, the company's focus on health products is mainly on throat lozenges, instant beverages, and solid beverages.
Gelonghui November 11th | Guizhou Yibai Pharmaceutical (600594.SH) expressed on the investor interaction platform that the company currently has anti-tumor products such as injection L-OHP, Kangsaidi capsules, and Aiyu capsules. Currently, the company's health products are mainly focused on throat lozenges, instant drinks, solid beverages, etc.
tianjin ringpu bio-technology (300119.SZ) is planning to acquire 15% equity of Zhong Rui Huapu to improve its strategic layout in the pet health sector.
Zhijian Financial APP news, tianjin ringpu bio-technology (300119.SZ) issued an announcement, to continue to improve the company's strategic layout in the pet health sector...
Uni Health International [02211] is now trading at 0.147 Hong Kong dollars, with a rise of 13.95%.
As of 13:21, Uni Health International [02211] reported 0.147 Hong Kong dollars, up 0.018 Hong Kong dollars or 13.95% from the closing price of 0.129 Hong Kong dollars yesterday. The turnover was 0.1336 million Hong Kong dollars. The highest price today was 0.142 Hong Kong dollars, and the lowest price was 0.117 Hong Kong dollars. Based on the closing price of yesterday, the 10-day average price is 0.13 Hong Kong dollars, and the 50-day average price is 0.08 Hong Kong dollars. The current PE ratio is 184.29 times, and the 14-day index is 66.67.
UNI HEALTH: 2023/24 ANNUAL REPORT
Beijing Yuanlong Yato Culture Dissemination (002878.SZ): The service enterprise clients are mainly concentrated in industries such as beauty, fast-moving consumer goods, internet, mobile, banks, insurance, and pharmaceuticals and healthcare.
On October 11th, Beijing Yuanlong Yato Culture Dissemination (002878.SZ) stated on the investor interaction platform that the company's service enterprise clients are mainly concentrated in industries such as beauty, fast-moving consumer goods, internet plus-related, mobile, banks, insurance, pharmaceuticals, and health. With the national policy vigorously promoting consumer spending, the improvement in end consumer purchasing power will directly drive clients' marketing demands, benefiting the expansion of the company's marketing business sector in terms of business scale and profitability. In addition, the company has established coverage in IP resources, IP content creation and dissemination, IP derivative product design and development, digital cultural and creative product development and operation, as well as B+C channel and IP e-commerce operation.
Ruiang Gene (688217.SH): Zhejiang Health has cumulatively reduced its shareholding by 0.9982%.
RegeneGene (688217.SH) announced on September 27th that it has received a notice from shareholder Zhejiang Da Health regarding the expiration of the period for the shareholding reduction plan of Shanghai RegeneGene Technology Co., Ltd., as of September 27, 2024, Zhejiang Da Health has reduced its holdings of the company's shares by 557,558 shares through centralized bidding trading, accounting for 0.9982% of the total share capital. The time range for this shareholding reduction plan has expired.
No Data
No Data